البلد: كندا
اللغة: الإنجليزية
المصدر: Health Canada
PRAVASTATIN SODIUM
BRISTOL-MYERS SQUIBB CANADA
C10AA03
PRAVASTATIN
40MG
TABLET
PRAVASTATIN SODIUM 40MG
ORAL
90
Prescription
HMG-COA REDUCTASE INHIBITORS
Active ingredient group (AIG) number: 0122563003; AHFS:
CANCELLED POST MARKET
2020-11-24
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr PRAVACHOL ® pravastatin sodium 20 and 40 mg Lipid Metabolism Regulator Bristol-Myers Squibb Canada Montréal, Canada ® Registered trademark of Bristol-Myers Squibb Company used under licence by Bristol-Myers Squibb Canada Date of Preparation: August 16, 1990 Date of Revision: March 4, 2020 Submission Control No: 234107 _ _ _ _ _Page 2 of 39_ TABLE OF CONTENTS PRODUCT MONOGRAPH .........................................................................................................1 TABLE OF CONTENTS .................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION...............................................................3 SUMMARY PRODUCT INFORMATION ........................................................................... 3 INDICATIONS AND CLINICAL USE ................................................................................. 3 CONTRAINDICATIONS ...................................................................................................... 5 WARNINGS AND PRECAUTIONS ..................................................................................... 5 ADVERSE REACTIONS ..................................................................................................... 11 DRUG INTERACTIONS ..................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................. 18 OVERDOSAGE ................................................................................................................... 19 ACTION AND CLINICAL PHARMACOLOGY ............................................................... 19 STORAGE AND STABILITY ............................................................................................. 21 DOSAGE FORMS, COMPOSITION AND PACKAGING ................................................ 21 PART II اقرأ الوثيقة كاملة